Mirror Site, please visit our main site www.timtec.com

Text Size

News and Articles

Plymouth Meeting, PA, June 26, 2002 – BIOMOL Research Laboratories, Inc. and TimTec Corporation. have announced a collaboration to provide the drug discovery research community with comprehensive chemical [diversity] libraries.

BIOMOL will design and market this series of products. TimTec brings access to a vast selection of small molecules - both synthetic and derived from nature. TimTec will be responsible for computational screening of compounds and producing the actual libraries. Applications of the first series, the MaxiVerse™ Chemical Diversity Libraries, will be lead generation; the follow-on series will include libraries for chemical genomics and proteomics research.

"This collection builds upon our current offering of ligand libraries," states Dr. Robert Zipkin, the president of BIOMOL, in reference to BIOMOL’s well-received Screen-Well Ligand Library Series. He continued, "We are excited about adding this phenomenal collection of potential drug leads to our product portfolio. Drug discovery research and high throughput techniques demand the availability of a comprehensive selection of small molecules at a high level of purity. The chemical libraries we will develop together will expedite the drug discovery process."

"Historically TimTec was focused on delivering most diversified organic compounds for screening synthesized both in in-house and various research centers from around the world. As a result we have created 2mln+ compounds library. Collaboration with BIOMOL will allow us to develop narrowly focused libraries in order to satisfy increasing demand from scientific community," states TimTec President Dr. Murat Niyazymbetov.

The MaxiVerse™ chemical diversity libraries will represent a breakthrough product for academic researchers who are carrying out screening for chemical genomics studies in addition to pharmaceutical high throughput screening groups. Customized libraries are also an option. The libraries will be supplied in 96-well plates in dry or liquid (DMSO solution, shipped in dry ice) forms. The hit compounds will be re-supplied in larger amounts. Customers will be also offered an opportunity to collaborate in building focused libraries around lead compounds.

About BIOMOL:

BIOMOL Research Laboratories, Inc., develops, produces and markets innovative reagents for signal transduction research and drug discovery, including enzymes, inhibitors, antibodies, neurochemicals and assay systems, plus compound libraries for receptor de-orphaning, ion channel characterization and chemical genomics. Founded in 1983, it is a leading provider of specialty biochemicals to both academic and industrial research organizations worldwide.

About TimTec:

TimTec Corporation. of Newark, DE is a full-service provider of compound acquisition for high-throughput screening. TimTec specialize in unique chemistry and possesses the optimal combination of in house synthesis and global sourcing of unique organic molecules. TimTec established a global network of thousands of scientists and research centers from around the world. Founded in 1995 TimTec is a leading provider of compounds for bioscreening, building blocks and intermediates, custom synthesis, sample handling, database managing tools and technologies.

Category: Press Releases

Database Access

Contact Us

P: 302-292-8500
F: 302-292-8520
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

eStore Product Search

IUPAC, Smiles, ID, MW, Name, CAS, MDL

Follow Us Message Us Friend Us Friend Us

eChemShop Chemicals, Equipment, Software

ChemDBsoft Chemical Database Software

Drug Discovery News

  • Osiris Therapeutics’ adult stem cell therapy Prochymal® received approval from Health Canada for the treatment of acute graft-vs-host disease (GvHD) in children who failed to respond to steroids. The company will have to carry out certain post-launch confirmatory studies. The decision gives Osiris the distinction of being the first company to win full marketing approval [...]

  • Scientists have adapted the algorithm used by Google’s web search engine to develop a computational program that can identify panels of biomarkers for cancer prognosis. Google’s PageRank algorithm takes into account the network of hyperlinks between web documents as well as the search terms themselves to determine which pages are most relevant to a particular [...]

  • Janssen Pharmaceuticals reported Phase III results demonstrating the efficacy of Nucynta® ER (extended release tapentadol) in managing pain associated with chronic diabetic peripheral neuropathy (DPN). Janssen says the data is consistent with that of a separate study reported in 2011 in patients with DPN. Nucynta ER is a centrally acting analgesic that acts as both [...]

  • Targeted cancer drug developer Ruga negotiated rights to Selexagen Therapeutics’ RAF kinase program. The firm claims the acquired technology addresses the drawbacks to BRAF inhibition as an approach to cancer therapy. Data has demonstrated that BRAF inhibition can actually induce adaptation in RAS-activated cells and promote the development of secondary skin lesions and RAS-mutated tumor [...]

  • XenoBiotic Laboratories established a partnership with Hungary-based Solvo Biotechnology to offer in vitro transporter services in the U.S. Solvo will transfer its efflux and uptake transporter assays to XBL’s research facilities in New Jersey. The services will be made available to American customers through both Solvo and XBL sales channels. Through this collaboration Solvo will [...]

  • Affymetrix signed a worldwide distribution agreement for ScreenCell’s isolation devices and dilution buffers for the collection of circulating tumor cells (CTCs) in peripheral blood. The QuantiGene® ViewRNA CTC platform, which consists of ScreenCell’s products and Affymetrix’ QuantiGene ViewRNA Assays, is now available from Affymetrix. The arrangement makes Affymetrix the exclusive distributor of ScreenCell products used [...]

  • An algal system for manufacturing recombinant proteins has provided scientists with the means to generate a malaria-blocking vaccine candidate based on two native unglycosylated Plasmodium falciparum surface proteins, Pfs25 and Pfs28. The University of California, San Diego researchers produced the two P. falciparum proteins in the chloroplasts of the widely used model alga Chlamydomonas reinhardtii, [...]

  • Agilent is buying Danish cancer in vitro diagnostics firm Dako for $2.2 billion in cash on a debt-free basis. Agilent says the acquisition is the largest in its history, and will complement its existing life science business and boost its presence in the clinical diagnostics market. “In the rapidly growing diagnostics market, Dako’s products and [...]

  • Aveo Oncology and partner Astellas Pharma Europe reported positive data from the pivotal Phase III study Viro-1, comparing the once-daily oral tyrosine kinase inhibitor candidate tivozanib with sorafenib in 517 patients with advanced renal cell carcinoma (RCC). Astellas says it plans to submit a marketing authorization application for tivozanib to the European authorities during the [...]

  • Evotec is adding Agilent Technologies’ RapidFire mass spectrometry analysis capabilities to its high-throughput screening facilities in Hamburg. RapidFire is an in-line solid-phase extraction technology. It enables ultrafast, direct analysis of native compounds for a variety of biochemical assays including routine ADME and lead discovery applications across a range of therapeutic areas. Evotec reports that it [...]